DTC "Brief Summary" Should Refer To Other Treatment Options, Blues Tell FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Prescribing information for direct-to-consumer ads should include a tagline encouraging consumers to consult their doctors for other treatment options, the Blue Cross/Blue Shield Association comments on FDA's DTC draft guidances say.
You may also be interested in...
FDA "Brief Summary" Changes Should Be Written In Regs - PhRMA
DTC draft guidance creates a regulatory "Catch-22" by going against current regulations, PhRMA says in comments. FDA's guidance on disease awareness ads oversteps the agency's authority in regulating unbranded ads, the group asserts.
FDA "Brief Summary" Changes Should Be Written In Regs - PhRMA
DTC draft guidance creates a regulatory "Catch-22" by going against current regulations, PhRMA says in comments. FDA's guidance on disease awareness ads oversteps the agency's authority in regulating unbranded ads, the group asserts.
Alternatives To Brief Summary Outlined In Draft Guidance
One of FDA's three draft guidances on DTC advertising requests that consumer-friendly language be used. Commissioner McClellan calls proposed brief summary alternatives a "win-win" and suggests manufacturers will be able to reduce their advertising costs as a result.